Polyhydraminos and Oligohydraminos

Polyhydramnios and Oligohydramnios: [Print] - eMedicine Pediatrics: Cardiac Disease an...
Page 1 of 11
emedicine.medscape.com
eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Neonatology
w GGv
Roland L Boyd, DO, FAAP, FACOP, Neonatologist, Section of Neonatology, Neonatal Services Limited
Brian S Carter, MD, FAAP, Professor of Pediatrics, Department of Pediatrics, Division of Neonatology, Vanderbilt University School
of Medicine; Co-director, Pediatric Advance Comfort Team, Vanderbilt Children's Hospital
Updated: Feb 14, 2008
Introduction
Background
The amniotic fluid that bathes the fetus is necessary for its proper growth and development. It cushions the fetus
from physical trauma, permits fetal lung growth, and provides a barrier against infection. Normal amniotic
fluid volume varies. The average volume increases with gestational age, peaking at 800-1000 mL, which coincides
with 36-37 weeks' gestation. An abnormally high level of amniotic fluid, polyhydramnios, alerts the clinician to
possible fetal anomalies. Inadequate volume of amniotic fluid, oligohydramnios, results in poor development of the
lung tissue and can lead to fetal death.
In pregnancies affected by polyhydramnios, approximately 20% of neonates are born with a congenital anomaly of
some type; therefore, the delivery of these newborns in a tertiary care setting is preferred. This article presents the
causes, outcomes, and treatments of polyhydramnios and oligohydramnios, as well as their effects on the
developing fetus and neonate.
Pathophysiology
Rupture of the membranes is the most common cause of oligohydramnios. However, because the amniotic fluid is
primarily fetal urine in the latter half of the pregnancy, the absence of fetal urine production or a blockage in the
fetus' urinary tract can also result in oligohydramnios. Fetal swallowing, which occurs physiologically, reduces the
amount of fluid, and an absence of swallowing or a blockage of the fetus' GI tract can lead to polyhydramnios.
Frequency
United States
Oligohydramnios occurs in 4% of pregnancies, and polyhydramnios occurs in 1% of pregnancies.
Mortality/Morbidity
• Chamberlin used ultrasonography to evaluate the perinatal mortality rate (PMR) in 7562 patients with high-
risk pregnancies.[1 ]The PMR of patients with normal fluid volumes was 1.97 deaths per 1000 patients. The
PMR increased to 4.12 deaths per 1000 patients with polyhydramnios and 56.5 deaths per 1000 patients with
oligohydramnios.
• Preterm labor and delivery occurs in approximately 26% of mothers with polyhydramnios. Other
complications include premature rupture of the membranes (PROM), abruptio placenta, malpresentation,
cesarean delivery, and postpartum hemorrhage.
• Studies show an increased risk of associated fetal anomalies in more severe forms of polyhydramnios. In a
series in 1990, 20% of cases of polyhydramnios involved associated fetal anomalies, including problems of
the GI system (40%), CNS (26%), cardiovascular system (22%), or genitourinary system (13%).[2 ]Among
these cases of polyhydramnios, multiple gestations occurred in 7.5%, 5% were due to maternal diabetes, and
http://emedicine.medscape.com/article/975821-print 03/06/2010
Polyhydramnios and Oligohydramnios: [Print] - eMedicine Pediatrics: Cardiac Disease an... Page 2 of 11
the remaining 8.5% were due to other causes. However, at least 50% of the patients had no associated risk
factors.
• The mortality rate in oligohydramnios is high. The lack of amniotic fluid allows compression of the fetal
abdomen, which limits movement of its diaphragm. In addition to chest wall fixation, the lack of amniotic fluid
flowing in and out of the fetal lung leads to pulmonary hypoplasia. Oligohydramnios is also associated with
meconium staining of the amniotic fluid, fetal heart conduction abnormalities, umbilical cord compression,
poor tolerance of labor, lower Apgar scores, and fetal acidosis. In cases of intrauterine growth restriction
(IUGR), the degree of oligohydramnios is often proportional to growth restriction, is frequently reflective of the
extent of placental dysfunction, and is associated with a corresponding increase in the PMR.
• In twin gestation with twin-to-twin transfusion, polyhydramnios may occur in the recipient twin, and
oligohydramnios may occur in the donor. This complication is associated with high morbidity and mortality
rates.
Age
No age variables are recognized.
Clinical
Physical
• Amniotic fluid
◦ The volume of the amniotic fluid is evaluated by visually dividing the mother's abdomen into 4
quadrants. The largest vertical pocket of fluid is measured in centimeters. The total volume is
calculated by multiplying this value by 4.
◦ Polyhydramnios is usually defined as an amniotic fluid index (AFI) of more than 24 cm or a single
pocket of fluid at least 8 cm in depth that results in an amniotic fluid volume of more than 2000 mL.
◦ Oligohydramnios is sonographically defined as an AFI less than 7 cm or the absence of a fluid pocket
2-3 cm in depth.
• Polyhydramnios
◦ Visual inspection may reveal a rapidly enlarging uterus in the pregnant mother.
◦ Multiple gestations are associated with polyhydramnios.
◦ Fetal abnormalities associated with polyhydramnios include neonatal macrosomia, fetal or neonatal
hydrops with anasarca, ascites, pleural or pericardial effusions, and GI tract obstruction (eg, duodenal
atresia, tracheoesophageal fistula).
◦ Skeletal malformations can also occur; these include congenital hip dislocation, clubfoot, and limb
reduction defect.
◦ Abnormalities in fetal movement are suggestive of primary neurologic abnormalities or are in
association with a genetic syndrome, such as polyploidy.
• Oligohydramnios
◦ When the oligohydramnios is associated with renal agenesis or dysgenesis, symptoms include a
marked deformation of the fetus due to of intrauterine constraint (Potter syndrome).
◦ Obstructive uropathies cause similar deformations, including external compression with a flattened
facies and epicanthal folds, hypertelorism, low-set ears, a mongoloid slant of the palpebral fissure, a
crease below the lower lip, and micrognathia. Thoracic compression may also occur.
◦ Oligohydramnios adversely affects fetal lung development, resulting in pulmonary hypoplasia that
typically leads to death from severe respiratory insufficiency. Other fetal deformations include bowed
legs, clubbed feet, a single umbilical artery, GI atresias, and a narrow chest secondary to external
compression. Infants are typically small for their stated gestational age (SGA). When an abdominal
mass is found on examination of the infant in this clinical setting, it often represents multicystic-
dysplastic kidney, enlarged urinary bladder, or prune-belly syndrome.
Causes
• Polyhydramnios: The underlying cause of the excessive amniotic fluid volume is obvious in some clinical
conditions and is not completely understood in others. Causes include the following:
◦ Twin gestation with twin-to-twin transfusion syndrome (increased amniotic fluid in the recipient twin
and decreased amniotic fluid in the donor) or multiple gestations
◦ Fetal anomalies, including esophageal atresia (usually associated with a tracheoesophageal fistula),
tracheal agenesis, duodenal atresia, and other intestinal atresias
◦ CNS abnormalities and neuromuscular diseases that cause swallowing dysfunction
◦ Congenital cardiac-rhythm anomalies associated with hydrops, fetal-to-maternal hemorrhage, and
parvovirus infection
◦ Poorly controlled maternal diabetes mellitus (Oligohydramnios may also be seen if severe vascular
disease is present.)
◦ Chromosomal abnormalities, most commonly trisomy 21, followed by trisomy 18 and trisomy 13.
◦ Fetal akinesia syndrome with absence of swallowing
• Oligohydramnios
◦ Fetal urinary tract anomalies, such as renal agenesis, polycystic kidneys, or any urinary obstructive
lesion (eg, posterior urethral valves)
◦ PROM and chronic leakage of the amniotic fluid
■ Chorioamnionitis is an additional important maternal complication from oligohydramnios due to
rupture of the membranes, which has an incidence of 21-74%.
■ The earlier chorioamnionitis occurs in pregnancy, the greater the fetal risk of
bronchopulmonary dysplasia (BPD), neurologic complications, pulmonary hypoplasia, and, in
severe cases, respiratory failure in the neonate.
◦ Placental insufficiency, as seen in pregnancy-induced hypertension (PIH), maternal diabetes, or
postmaturity syndrome when the pregnancy extends beyond 42 weeks' gestation
◦ Maternal use of prostaglandin synthase inhibitors or ACE inhibitors
Workup
Laboratory Studies
If premature delivery is anticipated with either oligohydramnios or polyhydramnios, the amniotic fluid lamellar body
count, lecithin-sphingomyelin (L:S) ratio, and phosphatidylglycerol (PG) concentration are helpful in determining the
maturity of the fetal lungs and, therefore, in assessing the likelihood of respiratory distress syndrome.
• Polyhydramnios
◦ Glucose tolerance test for mothers with suspected type 2 diabetes mellitus
◦ Fetal hydrops testing: If fetal hydrops is present, immunologic and fetal infection need to be
investigated. This should include screening for maternal antibodies to D, C, Kell, Duffy, and Kidd
antigens to determine maternal antibody production against the fetal red blood cells. Infections of the
fetus include cytomegalovirus (CMV), toxoplasmosis, syphilis, and parvovirus B19. The investigation
should include the following:
■ Venereal Disease Research Laboratories (VDRL) test to screen for syphilis
■ Immunoglobulin G (IgG) and immunoglobulin M (IgM) titers to evaluate for exposure to rubella,
CMV, toxoplasmosis and parvovirus
■ A test for congenital viruses in the amniotic fluid using the polymerase chain reaction
◦ Kleihauer-Betke test to evaluate fetal-maternal hemorrhage
◦ Hemoglobin Bart in patients of Asian descent (who may be heterozygous for alpha-thalassemia)
◦ Fetal karyotyping for trisomy 21, 13, and 18
• Oligohydramnios
◦ Test for systemic lupus erythematosus, which causes immune-mediated infarcts in the placenta and
placental insufficiency.
◦ Evaluate for PIH and hemolysis, elevated liver enzymes, and low platelet count (HELLP)
syndrome. Test for elevated blood pressure, proteinuria, elevated uric acid, increased liver function
test results, and low platelet count.
Imaging Studies
• Prenatal ultrasonography and polyhydramnios

◦ Evaluate fetal swallowing. A decrease in fetal deglutition occurs in anencephaly, trisomy 18, trisomy
21, muscular dystrophy, and skeletal dysplasia.
◦ Evaluate the fetal anatomy; assess for diaphragmatic hernia, lung masses, and the absence of the
stomach bubble (which is associated with esophageal atresia). The double-bubble sign or a dilated
duodenum suggests the possibility of duodenal atresia.
◦ Test for fetal arrhythmias and malformations that result in cardiac failure and hydrops.
◦ An abnormally large abdominal circumference may be observed with ascites and hydrops fetalis.
◦ A macrosomic fetus is observed in association with poorly controlled maternal diabetes.
◦ Assess the blood flow velocity in the anterior cerebral artery of the fetus for fetal anemia.
• Prenatal ultrasonography and oligohydramnios

◦ Perform serial measurements of the AFI during the pregnancy. If the mother is in the third trimester
and if the volume is less than 8 cm, suspect oligohydramnios. Levels less than 5 cm indicate
significant oligohydramnios.
◦ Visualize the fetal kidneys, collecting system, and bladder. If these are normal, suspect the chronic
leakage of amniotic fluid or PIH.
◦ Assess fetal growth. If PROM or urinary tract anomalies are absent, consider placental insufficiency
and IUGR.
◦ Uterine artery Doppler study findings may aid in the diagnosis of placental insufficiency.
◦ Postnatally, evaluate organ systems likely to be involved on the basis of the pregnancy history and
results of other prenatal evaluations. For more information, see Oligohydramnios.
Other Tests
• Testing of the infant is recommended, depending on the results of postnatal evaluation of the infant. Such
evaluation may include chromosome testing, testing for evidence of congenital infection, ultrasonography of
the genitourinary tract, and appropriate radiologic evaluation of the GI tract. ECG and echocardiography may
also be indicated.
Procedures
• Polyhydramnios
◦ Reductive amniocentesis may be performed and has contributed to prolonged pregnancy in patients
who are severely affected by hydramnios.[3 ]This procedure can reduce the risk of preterm labor,
PROM, umbilical cord prolapse, and placental abruption. However, if too much fluid is removed,
placental abruption may occur. Other risks of the procedure include infection, bleeding, and trauma to
the fetus.
◦ Laser ablation of placental vessels may be efficacious in cases of twin-to-twin transfusion syndrome.
• Oligohydramnios
◦ The transabdominal instillation of indigo carmine may be used to evaluate for PROM.
◦ The transcervical instillation of isotonic sodium chloride solution (ie, amnioinfusion) at the time of
delivery reduces the risk of cord compression, fetal distress and meconium dilution. It also reduces
the potential need for cesarean delivery.
Histologic Findings
• Examination of the placenta may be helpful in determining the cause of the polyhydramnios or
oligohydramnios.
Treatment
Medical Care
The first step is identifying the etiology of the abnormal volume of amniotic fluid. Medical care includes the use of
steroids to enhance fetal lung maturity if preterm delivery is anticipated.
• Polyhydramnios
◦ Patients with polyhydramnios tend to have a higher incidence of preterm labor secondary to
overdistention of the uterus.
◦ Schedule weekly or twice weekly perinatal visits and cervical examinations.
◦ Place patients on bed rest to decrease the likelihood of preterm labor.
◦ Perform serial ultrasonography to determine the AFI and document fetal growth.
◦ In cases of polyhydramnios associated with fetal hydrops secondary to fetal anemia, the direct
intravascular transfusion of erythrocytes (or infusion into the fetal abdomen) may improve the fetal
hematocrit and fetal congestive heart failure, thereby allowing prolongation of the pregnancy and
improving survival.
• Oligohydramnios
◦ Maternal bed rest and hydration promote the production of amniotic fluid by increasing the maternal
intravascular space. Bed rest may also help when PIH is present, allowing prolongation of the
pregnancy.
◦ Studies show that oral hydration, by having the women drink 2 liters of water, increases the AFI by
30%.
Consultations
• A specialist in maternal-fetal medicine should be consulted when significant oligohydramnios or

polyhydramnios is present, especially when the condition is unexplained, involves hydrops fetalis, or is
associated with congenital malformations.
• Genetic counseling may be helpful in cases in which congenital anomalies are identified.
• Consult a neonatologist, pediatric surgeon, pediatric cardiologist, pediatric nephrologist, or other genetics
specialists as required to care for the infant.
Diet
• In cases of polyhydramnios in which maternal diabetes is suspected, perform a glucose tolerance test. If the
test results are positive, treat the mother with an American Diabetes Association (ADA) diet. Insulin is rarely
needed.
Medication
Most cases of polyhydramnios respond in the first week of treatment with indomethacin.[4,5,6 ]The approach appears
to be highly effective (90-100% in some studies), provided that the cause is not hydrocephalus or a neuromuscular
disorder that alters fetal swallowing.
Prostaglandin inhibitors
When administered to pregnant women with polyhydramnios, these drugs can reduce fetal urinary flow, decreasing
the volume of amniotic fluid.
Indomethacin (Indocin)
Rapidly absorbed; metabolism occurs in liver by demethylation, deacetylation, and glucuronide conjugation; inhibits
prostaglandin synthesis.
Dosing
Adult
25 mg PO q6h
Pediatric
Interactions
Coadministration with aspirin increases risk of serious NSAID-related adverse effects; probenecid may increase
concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers;
may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of
bleeding); may increase risk of methotrexate toxicity; may increase phenytoin levels when administered concurrently
Contraindications
Documented hypersensitivity; GI bleeding; renal insufficiency
Precautions
Pregnancy
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Precautions
Can cause fetal renal and CNS complications; associated with premature closure of the fetal ductus arteriosus when
administered near term; acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal
papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or
compromised renal perfusion; reversible leukopenia may occur (discontinue if persistent leukopenia,
granulocytopenia, or thrombocytopenia present).
Periventricular leukomalacia has been reported in infants whose mothers have received indomethacin as a tocolytic.
Follow-up
Further Inpatient Care
• Polyhydramnios: See recommendations for oligohydramnios below.
• Oligohydramnios
◦ Consider hospitalizing and thoroughly evaluating the mother in cases diagnosed after 26-33 weeks'
gestation.
◦ If the fetus does not have an anomaly, delivery should be performed if the biophysical profile is
nonreassuring.
◦ The instillation of isotonic sodium chloride solution in the second trimester may be of benefit in some
patients. Use transabdominal amnioinfusion to instill 400-600 mL, which may improve visualization for
ultrasonography and increase volume of the amniotic fluid.
◦ In cases associated with postmaturity, review pregnancy dating. If the gestation is truly longer than
term, deliver the fetus by means of either induction or cesarean delivery.
◦ If meconium is present during labor, administer amnioinfusion therapy to reduce the potential for fetal
distress and prenatal aspiration.
Transfer
• Transfer to a tertiary center is indicated when the pregnant woman has a high likelihood of maternal illness,
preterm delivery, or infant problems that may require the resources of a tertiary care facility.
Complications
• Polyhydramnios
◦ Risks and complications of amnioinfusion include amniotic fluid embolism, maternal respiratory
distress, increased maternal uterine tone, and transient fetal respiratory distress. An increase in the
risk of maternal or fetal infection is not substantiated.
◦ Risks of amniocentesis include fetal loss (1-2%). Other complications are placental abruption, preterm
labor, fetal-maternal hemorrhage, maternal Rh sensitization, and fetal pneumothorax. The risk of fetal
infection is slightly increased.
• Oligohydramnios
◦ The primary complications are those related to fetal distress before or during labor.
◦ The risk of fetal infection is increased in the presence of prolonged rupture of the membranes.
Prognosis
• Polyhydramnios
◦ If the condition is not associated with any other findings, the prognosis is usually good.
◦ According Desmedt et al, the PMR in polyhydramnios associated with a fetal or placental
malformation was 61%.[7 ]
◦ As mentioned in Background and Mortality/Morbidity 20% of infants with polyhydramnios have some
anomaly; in these cases, the prognosis depends on the severity of the anomaly.
◦ Studies show that, as the severity of polyhydramnios increases, the likelihood of determining the
etiology increases.
◦ In cases of mild polyhydramnios, the likelihood of finding a significant problem is only about 16.5%;
this should be communicated to the parents.
• Oligohydramnios
◦ In renal agenesis, the mortality rate is 100%.
◦ Milder forms of renal dysplasia or obstructive uropathy can be associated with mild-to-severe degree
of pulmonary hypoplasia and long-term renal failure.
◦ In cases of pulmonary hypoplasia, the effectiveness of many treatments such as the administration of
surfactant, high frequency ventilation, and nitric oxide has not been established. The prognosis in
these cases is related to the volume of amniotic fluid and the gestational age at which
oligohydramnios develops.
Miscellaneous
Medicolegal Pitfalls
• Failure to perform ultrasonography in a pregnancy complicated by either polyhydramnios or oligohydramnios

to investigate associated or contributory fetal anomalies
• The underlying anomalies may determine the outcome of the fetus, as well as the treatment and outcome of
the neonate. As appropriate, specialists should be consulted, and the patient should be transferred in a
timely fashion to optimize the outcome of the pregnancy and to reduce the risk of perinatal mortality.
References
1. Chamberlain PF, Manning FA, Morrison I, et al. Ultrasound evaluation of amniotic fluid volume. II. The
relationship of increased amniotic fluid volume to perinatal outcome. Am J Obstet Gynecol. Oct 1 1984;150
(3):250-4. [Medline].
2. Ben-Chetrit A, Hochner-Celnikier D, Ron M, Yagel S. Hydramnios in the third trimester of pregnancy: a

change in the distribution of accompanying fetal anomalies as a result of early ultrasonographic prenatal
diagnosis. Am J Obstet Gynecol. May 1990;162(5):1344-5. [Medline].
3. Abdel-Fattah SA, Carroll SG, Kyle PM, Soothill PW. Amnioreduction: how much to drain?. Fetal Diagn
Ther. Sep-Oct 1999;14(5):279-82. [Medline].
4. Cabrol D, Jannet D, Pannier E. Treatment of symptomatic polyhydramnios with indomethacin. Eur J Obstet
Gynecol Reprod Biol. May 1996;66(1):11-5. [Medline].
5. Kramer WB, Van den Veyver IB, Kirshon B. Treatment of polyhydramnios with indomethacin. Clin
Perinatol. Sep 1994;21(3):615-30. [Medline].
6. Mamopoulos M, Assimakopoulos E, Reece EA, et al. Maternal indomethacin therapy in the treatment of
polyhydramnios. Am J Obstet Gynecol. May 1990;162(5):1225-9. [Medline].
7. Desmedt EJ, Henry OA, Beischer NA. Polyhydramnios and associated maternal and fetal complications in
singleton pregnancies. Br J Obstet Gynaecol. Dec 1990;97(12):1115-22. [Medline].
8. Biggio JR Jr, Wenstrom KD, Dubard MB, Cliver SP. Hydramnios prediction of adverse perinatal
outcome. Obstet Gynecol. Nov 1999;94(5 Pt 1):773-7. [Medline].
9. Brace RA, Resnik R. Dynamics and disorders of amniotic fluid. In: Creasy RK, Resnik R, eds. Maternal-Fetal
Medicine. 4th ed. 1999:632-43.
10. Fanaroff AA, Martin RJ. Diseases of the fetus and infant. In: Neonatal-Perinatal Medicine. 6th ed. 1997:315-9.
11. Harrison MR, Golbus MS, Filly RA. Prenatal diagnosis and treatment. In: The Unborn Patient. 2nd
ed. 1990:139-49.
12. Hill LM, Breckle R, Thomas ML, Fries JK. Polyhydramnios: ultrasonically detected prevalence and neonatal
outcome. Obstet Gynecol. Jan 1987;69(1):21-5. [Medline].
13. Jones KL. Oligohydramnios sequence. In: Smith's Recognizable Patterns of Human Malformation. 5th
ed. 1997.
14. Kilpatrick SE. Histologic prognostication in soft tissue sarcomas: grading versus subtyping or both? A
comprehensive review of the literature with proposed practical guidelines. Ann Diagn Pathol. Feb 1999;3
(1):48-61. [Medline].
15. Macri CJ, Schrimmer DB, Leung A, et al. Prophylactic amnioinfusion improves outcome of pregnancy
complicated by thick meconium and oligohydramnios. Am J Obstet Gynecol. Jul 1992;167(1):117-
21. [Medline].
16. Morales WJ, Talley T. Premature rupture of membranes at <25 weeks: a management dilemma. Am J Obstet
Gynecol. Feb 1993;168(2):503-7. [Medline].
17. Phelan JP, Ahn MO, Smith CV, et al. Amniotic fluid index measurements during pregnancy. J Reprod
Med. Aug 1987;32(8):601-4. [Medline].
18. Pitt C, Sanchez-Ramos L, Kaunitz AM, Gaudier F. Prophylactic amnioinfusion for intrapartum
oligohydramnios: a meta- analysis of randomized controlled trials. Obstet Gynecol. Nov 2000;96(5 Pt 2):861-
6. [Medline].
Polyhydramnios and Oligohydramnios: [Print] - eMedicine Pediatrics: Cardiac Disease ... Page 10 of 11
19. Rib DM, Sherer DM, Woods JR Jr. Maternal and neonatal outcome associated with prolonged premature
rupture of membranes below 26 weeks' gestation. Am J Perinatol. Sep 1993;10(5):369-73. [Medline].
20. Schumacher B, Moise KJ Jr. Fetal transfusion for red blood cell alloimmunization in pregnancy. Obstet
Gynecol. Jul 1996;88(1):137-50. [Medline].
21. Vergani P, Ghidini A, Locatelli A, et al. Risk factors for pulmonary hypoplasia in second-trimester premature
rupture of membranes. Am J Obstet Gynecol. May 1994;170(5 Pt 1):1359-64. [Medline].
22. Xiao ZH, Andre P, Lacaze-Masmonteil T, et al. Outcome of premature infants delivered after prolonged
premature rupture of membranes before 25 weeks of gestation. Eur J Obstet Gynecol Reprod
Biol. May 2000;90(1):67-71. [Medline].
Keywords
polyhydramnios, oligohydramnios, too much amniotic fluid, too little amniotic fluid, oligoamnios, oligamnios, fetal
lung development, membrane rupture, fetal urine, fetal swallowing, Potter syndrome, premature rupture of the
membranes, PROM, abruptio placenta, malpresentation, cesarean delivery, postpartum hemorrhage, pulmonary
hypoplasia, meconium staining of the amniotic fluid, fetal heart conduction abnormalities, umbilical cord
compression, poor tolerance of labor, lower Apgar scores, fetal acidosis, intrauterine growth restriction, IUGR,
multiple gestations, neonatal macrosomia, fetal hydrops, neonatal hydrops, ascites, pleural effusion, pericardial
effusion, GI tract obstruction, duodenal atresia, tracheoesophageal fistula, Potter syndrome, multicystic-dysplastic
kidney, enlarged urinary bladder, prune-belly syndrome
Contributor Information and Disclosures
Author
Roland L Boyd, DO, FAAP, FACOP, Neonatologist, Section of Neonatology, Neonatal Services Limited
Roland L Boyd, DO, FAAP, FACOP is a member of the following medical societies: American Academy of
Osteopathy, American Academy of Pediatrics, and American College of Osteopathic Pediatricians
Disclosure: Nothing to disclose.
Coauthor(s)
Brian S Carter, MD, FAAP, Professor of Pediatrics, Department of Pediatrics, Division of Neonatology, Vanderbilt
University School of Medicine; Co-director, Pediatric Advance Comfort Team, Vanderbilt Children's Hospital
Brian S Carter, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy
of Pediatrics, National Hospice and Palliative Care Organization, and National Perinatal Association
Medical Editor
Ted Rosenkrantz, MD, Head, Division of Neonatal-Perinatal Medicine, Professor, Departments of Pediatrics and
Obstetrics/Gynecology, University of Connecticut School of Medicine
Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American
Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric
Research, and Society for Pediatric Research
Pharmacy Editor
Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy,
Pharmacy Editor, eMedicine.com, Inc
Polyhydramnios and Oligohydramnios: [Print] - eMedicine Pediatrics: Cardiac Disease ... Page 11 of 11
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker
recommendation
Managing Editor
David A Clark, MD, Chairman, Professor, Department of Pediatrics, Albany Medical College
David A Clark, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of
Pediatrics, American Pediatric Society, Christian Medical & Dental Society, Medical Society of the State of New
York, New York Academy of Sciences, and Society for Pediatric Research
CME Editor
Carol L Wagner, MD, Professor of Pediatrics, Medical University of South Carolina

Carol L Wagner, MD is a member of the following medical societies: American Academy of Pediatrics, American
Chemical Society, American Medical Women's Association, American Public Health Association, American Society
for Bone and Mineral Research, American Society for Clinical Nutrition, Massachusetts Medical Society, National
Perinatal Association, and Society for Pediatric Research
Chief Editor
Ted Rosenkrantz, MD, Head, Division of Neonatal-Perinatal Medicine, Professor, Departments of Pediatrics and
Obstetrics/Gynecology, University of Connecticut School of Medicine
Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American
Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric
Research, and Society for Pediatric Research
Further Reading
© 1994- 2010 by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)

Polyhydraminos and Oligohydraminos

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Polyhydraminos and Oligohydraminos

Uploaded by

Copyright:

Available Formats

Polyhydramnios and Oligohydramnios: [Print] - eMedicine Pediatrics: Cardiac Disease an...

Oligohydramnios occurs in 4% of pregnancies, and polyhydramnios occurs in 1% of pregnancies.

• Prenatal ultrasonography and polyhydramnios

• Prenatal ultrasonography and oligohydramnios

• A specialist in maternal-fetal medicine should be consulted when significant oligohydramnios or

Documented hypersensitivity; GI bleeding; renal insufficiency

Further Inpatient Care

• Polyhydramnios: See recommendations for oligohydramnios below.

• Failure to perform ultrasonography in a pregnancy complicated by either polyhydramnios or oligohydramnios

2. Ben-Chetrit A, Hochner-Celnikier D, Ron M, Yagel S. Hydramnios in the third trimester of pregnancy: a

Contributor Information and Disclosures

Carol L Wagner, MD, Professor of Pediatrics, Medical University of South Carolina

You might also like